- GlobeNewswire•28 days ago
CAMBRIDGE, Mass., Sept. 29, 2016-- Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode ...
- GlobeNewswire•last monthEpizyme Establishes Collaboration with Foundation Medicine to Support Tazemetostat Phase 2 Clinical Trial
CAMBRIDGE, Mass., Sept. 21, 2016-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement ...
Epizyme, Inc. (EPZM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||8.95 - 9.20|
|52wk Range||7.02 - 18.29|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.61|
|Avg Vol (3m)||380,960|
|Dividend & Yield||N/A (N/A)|